Yes, Wegovy is FDA-approved specifically for chronic weight management. It contains semaglutide, a compound that mimics a natural gut hormone to reduce appetite, and it’s prescribed alongside diet and exercise for people who meet certain weight criteria. In March 2024, the FDA also approved Wegovy to reduce the risk of heart attack, stroke, and cardiovascular death in adults with heart disease who have obesity or are overweight.
Who Qualifies for a Prescription
Wegovy isn’t available to anyone who simply wants to lose a few pounds. The FDA approval sets specific thresholds. You’re eligible if you’re an adult with a BMI of 30 or higher, which is the clinical definition of obesity. You can also qualify with a BMI of 27 or higher if you have at least one weight-related health condition such as high blood pressure, type 2 diabetes, or high cholesterol.
The drug is also approved for adolescents aged 12 and older whose BMI falls at or above the 95th percentile for their age and sex, which corresponds to obesity in pediatric terms.
How Wegovy Causes Weight Loss
Wegovy works by activating receptors for a hormone called GLP-1 that your body already produces in small amounts after eating. When semaglutide binds to these receptors in the brain, it triggers a chain of effects that make you feel full sooner and stay full longer.
The drug reaches a part of the brainstem that lacks the usual protective barrier between blood and brain tissue, making it especially responsive to circulating signals. There, it dials down the reward value of food by influencing dopamine activity and boosts feelings of fullness through serotonin pathways. Those signals travel to the hypothalamus, which acts as the brain’s appetite control center. In the hypothalamus, semaglutide turns up appetite-suppressing chemical signals while turning down hunger-promoting ones. It also inhibits neurons that normally stimulate the drive to eat. The net result is that you genuinely want less food, rather than relying on willpower alone to eat less.
How It’s Taken
Wegovy is a once-weekly injection you give yourself under the skin using a prefilled pen. The recommended sites are your lower abdomen (at least two inches from your belly button), your upper thigh, or your upper arm. You rotate the injection site each week.
To minimize side effects, the dose ramps up gradually over about four months:
- Weeks 1 through 4: 0.25 mg
- Weeks 5 through 8: 0.5 mg
- Weeks 9 through 12: 1 mg
- Weeks 13 through 16: 1.7 mg
- Week 17 onward: 2.4 mg (maintenance dose)
Some adults stay at 1.7 mg as their maintenance dose if the full 2.4 mg isn’t tolerated well.
How Wegovy Differs From Ozempic
Both Wegovy and Ozempic contain the same active ingredient, semaglutide, and are made by the same manufacturer. The difference is in their approved uses and doses. Ozempic is approved for type 2 diabetes management, while Wegovy is approved for weight loss. Wegovy’s maximum dose is 2.4 mg per week compared to Ozempic’s 2 mg, which means it delivers more of the drug at the highest prescribed level. Some doctors prescribe Ozempic off-label for weight loss, but Wegovy is the version specifically designed and studied for that purpose.
Common Side Effects
Digestive issues are by far the most frequent complaint. The most common side effects occurring in at least 5% of patients include nausea, diarrhea, vomiting, constipation, abdominal pain, heartburn, bloating, gas, and fatigue. Headache, dizziness, and hair loss also appear on that list. The gradual dose increase is specifically designed to give your body time to adjust, but these symptoms still cause some people to stop treatment. In clinical trials, 4.3% of patients on Wegovy discontinued due to gastrointestinal side effects, compared to 0.7% on placebo. Severe digestive reactions occurred in about 4% of patients.
Among adolescents, gastrointestinal problems were even more common, affecting 62% of those on Wegovy versus 42% on placebo, though fewer teens dropped out because of them.
Serious Safety Concerns
Wegovy carries a boxed warning, the FDA’s most prominent safety alert, regarding a risk of thyroid tumors. In animal studies, semaglutide caused thyroid C-cell tumors. Whether this translates to humans isn’t fully established, but the drug is contraindicated if you have a personal or family history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2. If you have either of these, Wegovy is not an option.
What to Realistically Expect
Weight loss with Wegovy is gradual. The first four months involve dose escalation, so meaningful results typically build over time rather than appearing immediately. Most of the effect comes from reduced appetite, meaning you’ll naturally eat less without the same level of hunger you’d experience through dieting alone. The drug is intended for long-term use. Stopping it often leads to weight regain, because the appetite-suppressing effects end when the medication does.
Wegovy works best when paired with changes to diet and physical activity. It’s not a standalone fix, but for people who qualify, it provides a biological assist that makes sustained calorie reduction significantly easier to maintain.